Argos Therapeutics, Inc. is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ARGS’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Argos Therapeutics could be a solid choice for investors.

Current Quarter Estimates for ARGS

In the past 30 days, 3 estimates have gone higher for Argos Therapeutics while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 48 cents a share 30 days ago, to a loss of 40 cents today, a move of 16.7%.

Current Year Estimates for ARGS

Meanwhile, Argos Therapeutics’s current year figures are also looking quite promising, with 4 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $2.12 per share 30 days ago to a loss of $1.64 per share today, an increase of 22.6%.

Bottom Line

The stock has also started to move higher lately, adding 8.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>